The U.S. FDA has approved Bristol Myers Squibb's CAR T cell therapy Breyanzi for treating relapsed or refractory follicular lymphoma.

Genentech Announces Favorable Phase Ib Outcomes for Dual GLP-1/GIP Receptor Agonist CT-388 in Obesity Patients.

A2 Biotherapeutics has reported the administration of the initial dose to the first participant in the Phase 1 clinical trial of A2B694.

Elinzanetant greatly decreases the occurrence and intensity of moderate to severe hot flashes tied to menopause.

Pheast Therapeutics revealed the initial showcasing of preclinical data for PHST001, an anti-CD24 antibody drug candidate.

Azitra, Inc. Reveals Encouraging Preclinical Data on ATR-12 and Clinical Plan for Netherton Syndrome at ASGCT Annual Conference.

Eisai Begins Submission of Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) Subcutaneous Maintenance Dosing in Early Alzheimer's, Fast Track Status.

PTC Therapeutics, Inc. revealed today that the FDA has officially received the Biologics License Application for Upstaza™ (eladocagene exuparvovec), a gene therapy aimed at treating AADC deficiency.

Verismo Therapeutics announced that the FDA has approved a Phase 1 clinical trial for SynKIR™-310 to evaluate its effectiveness for NHL.

This approval allows for the commencement of the Phase 3 Polaris-AD trial for AR1001 in early Alzheimer's Disease in China starting May 11th, 2024.

Fulcrum Therapeutics and Sanofi sign an agreement for Losmapimod's development and marketing in treating Facioscapulohumeral Muscular Dystrophy.

Senti Bio reports initial dosing in a Phase 1 trial for SENTI-202, targeting recurrent or treatment-resistant blood cancers like Acute Myeloid Leukemia.